SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab
The SUVmax-IPI represents a promising prognostic tool for patients with metastatic NSCLC who received at least 3 months of nivolumab, integrating metabolic and inflammatory parameters to predict survival outcomes.
Authors
- Gamze Gököz Doğu (ORCID: https://orcid.org/0000-0001-8142-0362)
- Bilgin Demir (ORCID: https://orcid.org/0000-0003-4380-9419)
- Mustafa Şahbazlar (ORCID: https://orcid.org/0000-0003-1857-593X)
- Nagihan Kolkıran (ORCID: https://orcid.org/0000-0001-9344-7212)
- Atike Pınar Erdoğan (ORCID: https://orcid.org/0000-0003-4859-7574)
- Özgür Tanrıverdi (ORCID: https://orcid.org/0000-0002-0598-7284)
- Kübra Canaslan (ORCID: https://orcid.org/0000-0001-7705-3926)
- Ferhat Ekinci (ORCID: https://orcid.org/0000-0002-9317-942X)
- İlkay Tuğba Ünek (ORCID: https://orcid.org/0000-0002-9124-6123)
- Oktay Demirkıran (ORCID: https://orcid.org/0000-0003-1319-9381)
- Semra Taş (ORCID: https://orcid.org/0000-0002-9441-9210)
- Güler Nur Teküstün
Institutions
- Manisa Celal Bayar University (TR)
- Dokuz Eylül University (TR)
- Pamukkale University (TR)
- Adnan Menderes University (TR)
- Muğla University (TR)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3390/curroncol32100566
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Manisa Celal Bayar Üniversitesi